Diabetes drug dapagliflozin may protect hearts after attack

NCT ID NCT05050500

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether the diabetes drug dapagliflozin can reduce inflammation and improve outcomes in people with type 2 diabetes who recently had a heart attack. Researchers gave 143 patients either dapagliflozin or standard care for 6 months. They measured heart complications like another heart attack, stroke, or death, as well as levels of inflammatory markers in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
dapagliflozin (a diabetes drug that also helps the heart)
What this could lead to
If successful, this could show that adding dapagliflozin to standard care after a heart attack reduces inflammation and lowers the risk of further heart problems in people with type 2 diabetes.
What could go wrong
This is a small, single-center Phase 4 study with only 143 participants. Results may not apply to all patients, and the drug may not show a clear benefit over standard therapy alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mengmei Li

    Qingdao, Shandong, 266042, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.